源自Netrin-1/DCC复合物的Netrin-1靶向肽探针开发及其在肿瘤无创成像中的应用

《Bioorganic Chemistry》：Development of Netrin-1-targeted peptide probes derived from the Netrin-1/DCC complex for noninvasive imaging of tumors

　　

This is a research article describing the rational design and development of novel Netrin-1-targeted peptide imaging probes for cancer diagnosis.

## Core Problem

Netrin-1 is overexpressed in non-small cell lung cancer (NSCLC) and breast cancer, making it a promising biomarker, but noninvasive tools for quantitative imaging of its expression were lacking. Existing antibody-based probes suffer from poor pharmacokinetics (slow clearance, tissue retention, immunogenicity), while previously developed peptide probes had suboptimal binding affinity and in vivo stability.

## Key Innovations

### 1. Structure-Based Rational Design Approach
The authors used the **crystal structure of the Netrin-1/DCC complex** (PDB ID: 4URT) as a structural template. They identified critical DCC residues within 5 ? of Netrin-1 at the binding interface and connected them into lead peptide sequences (L1 and L2), rather than relying on empirical screening.

### 2. Systematic Computational Optimization Pipeline
Three complementary in silico methods were applied:
- **Molecular docking** – to validate binding mode and affinity
- **Alanine scanning** (FoldX) – to identify key residues contributing to binding energy
- **Virtual amino acid mutation** – to optimize sequences for enhanced affinity, stability, and hydrophilicity

This yielded two optimized peptides: **YP8** and **LE7**.

### 3. Superior Peptide LE7 / [68Ga]Ga-NOTA-LE7 PET Tracer
The resulting [68Ga]Ga-NOTA-LE7 demonstrated clear advantages over the alternative YP8:
| Metric | [68Ga]Ga-NOTA-LE7 | Comparison |
|---|---|---|
| **Binding affinity** | K_D = 13.51 nM | Better than prior peptide probes (Gd-K: 290 nM; [68Ga]Ga-DKP: 36.85 nM) |
| **In vivo metabolic stability** | >90% intact at 60 min | Significantly enhanced |
| **Tumor-to-background ratio** | Significantly improved | Higher imaging contrast |
| **Tumor specificity** | Robust uptake in Netrin-1? A549 (NSCLC) and 4T1 (breast) tumors; minimal in Netrin-1? MDA-MB-231 | Confirms targeting specificity |

### 4. Multimodal Imaging Platform
- **PET modality**: [68Ga]Ga-NOTA-LE7 for whole-body quantitative in vivo imaging
- **NIRF modality**: ICG-LE7 probe for intraoperative fluorescence-guided surgical resection

These two modalities complement each other — PET for preoperative staging and ICG-LE7 for real-time surgical guidance.

## Broader Significance

- **Clinical relevance**: Netrin-1 is overexpressed in ~60% of metastatic breast cancers and strongly correlated with poor prognosis, making this tool valuable for **patient stratification** for Netrin-1-targeted therapies.
- **Methodological contribution**: The workflow — crystal structure → residue identification → alanine scanning → virtual mutagenesis → radiotracer development — establishes a **reproducible paradigm** for developing high-affinity peptide probes targeting other tumor-associated biomarkers (e.g., HER2, Trop2, FGFR1).
- **Addressing unmet needs**: Overcomes the poor stability and moderate affinity limitations of prior peptide probes, moving toward clinical-translation-ready standards.